Compare TEVA & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEVA | BDX |
|---|---|---|
| Founded | 1901 | 1897 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.5B | 48.2B |
| IPO Year | 1996 | 1998 |
| Metric | TEVA | BDX |
|---|---|---|
| Price | $40.88 | $188.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 15 |
| Target Price | $47.17 | ★ $194.08 |
| AVG Volume (30 Days) | ★ 5.3M | 1.7M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 2.24% |
| EPS Growth | ★ 183.45 | N/A |
| EPS | N/A | ★ 1.59 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.39 | $2.39 |
| P/E Ratio | ★ N/A | $117.84 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $18.83 | $140.11 |
| 52 Week High | $42.02 | $213.08 |
| Indicator | TEVA | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 62.59 | 62.07 |
| Support Level | $30.41 | $175.60 |
| Resistance Level | N/A | $192.41 |
| Average True Range (ATR) | 1.06 | 3.83 |
| MACD | 0.07 | 0.84 |
| Stochastic Oscillator | 69.76 | 91.14 |
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.